Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.58 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30663026 | 1.00 | DDB1 (0.58) | DDB1CRBNJAK2JAK1TYK2 | |
| SCHEMBL30662909 | 0.96 | DDB1 (0.55) | DDB1CRBNJAK2JAK1HPGDS | |
| SCHEMBL30663027 | 0.96 | DDB1 (0.55) | DDB1CRBNJAK2JAK1HPGDS | |
| SCHEMBL26635751 | 0.96 | DDB1 (0.61) | DDB1CRBNJAK2JAK1TYK2 | |
| SCHEMBL26925408 | 0.89 | DDB1 (0.54) | DDB1CRBNJAK2JAK1TYK2 | |
| SCHEMBL30732069 | 0.89 | DDB1 (0.54) | DDB1CRBNJAK2JAK1TYK2 | |
| SCHEMBL26636374 | 0.88 | DDB1 (0.61) | DDB1CRBN | |
| SCHEMBL26636043 | 0.88 | DDB1 (0.61) | DDB1CRBN | |
| SCHEMBL31444076 | 0.86 | DDB1 (0.64) | DDB1CRBNJAK2JAK1TYK2 | |
| SCHEMBL31314089 | 0.86 | DDB1 (0.54) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519259-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | TREELINE BIOSCIENCES INC (US) | 2023-12-07 | — | — | US | disclosed |
| WO-2023215482-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | DDB1 188/4885CRBN 3024/4885JAK2 1104/4885 |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | DDB1 188/4885CRBN 3024/4885JAK2 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.